Results 231 to 240 of about 271,547 (325)

The Impact of Early Antimalarial Adherence on Future Acute Care Utilization and Cost among Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients: A Population‐based Study

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the association between early antimalarial adherence and future acute care utilization and cost in a population‐based cohort of incident rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Methods All patients with incident RA/SLE and new antimalarial use in British Columbia, Canada, between 01/1997 and 03/2022 with at
Md Rashedul Hoque   +7 more
wiley   +1 more source

Implementation of the ICD-11 CDDR in China. [PDF]

open access: yesWorld Psychiatry
Long J   +6 more
europepmc   +1 more source

Performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Calculator in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Evaluate performance of the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) calculator in rheumatoid arthritis (RA). Methods Patients with RA were matched up to 10 controls on age, sex, and enrollment year using national Veterans Health Administration (VHA), Medicare, and National Death Index data (2006‐2020).
Tate M. Johnson   +13 more
wiley   +1 more source

Cultural considerations in the classification of mental disorders: why and how in ICD-11

open access: yesBMC Medicine, 2020
Oye Gureje   +3 more
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang   +6 more
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy